EGFR and head and neck squamous cell carcinoma: EMT-related resistance to the EGFR inhibitor Erlotinib can be induced via nerve growth factor (NGF) and tropomyosin receptor kinase A TrkA), which are both elevated in HNSCC and predict poor survival [140].